Literature DB >> 12546636

ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men.

Felix Böhm1, John Pernow, Jonas Lindström, Gunvor Ahlborg.   

Abstract

The contribution of the endothelin (ET) receptors ET(A) and ET(B) to basal vascular tone and ET-1-induced vasoconstriction in the renal and splanchnic vasculature was investigated in six healthy humans. ET-1 was infused alone and in combination with the selective ET(A) receptor antagonist BQ123 or the selective ET(B) receptor antagonist BQ788 on three different occasions. BQ123 did not affect basal arterial blood pressure, splanchnic vascular resistance (SplVR) or renal vascular resistance (RVR), but inhibited the increase in vascular resistance induced by ET-1 [64+/-18 versus -1+/-7% in SplVR ( P <0.05); 36+/-6 versus 12+/-3% in RVR ( P <0.0001)]. BQ788 increased basal SplVR and RVR [38+/-16% ( P =0.01) and 21+/-5% ( P <0.0001) respectively], and potentiated the ET-1-induced vasoconstriction. Plasma ET-1 increased more after ET(B) blockade than under control conditions or after ET(A) blockade. These findings suggest that the ET(A) receptor mediates the splanchnic and renal vasoconstriction induced by ET-1 in healthy humans. The ET(B) receptor seems to function as a clearance receptor and may modulate vascular tone by altering the plasma concentration of ET-1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12546636     DOI: 10.1042/CS20020192

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

1.  Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.

Authors:  Matthew R Lammi; Stephen C Mathai; Lesley Ann Saketkoo; Robyn T Domsic; Christine Bojanowski; Daniel E Furst; Virginia D Steen
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

2.  Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial.

Authors:  D Tripathi; G Therapondos; J W Ferguson; D E Newby; D J Webb; P C Hayes
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

Review 3.  Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer.

Authors:  Lowell Ling; Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 4.  Endothelin, astrocytes and glaucoma.

Authors:  Ganesh Prasanna; Raghu Krishnamoorthy; Thomas Yorio
Journal:  Exp Eye Res       Date:  2010-09-16       Impact factor: 3.467

5.  Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats.

Authors:  Qing-Hong Du; Lin Han; Jun-Jie Jiang; Ya Xu; Wei-Hong Li; Peng-Tao Li; Xin-Yue Wang; Xu Jia
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

6.  Bosentan effects in hypoxic pulmonary vasoconstriction: Preliminary study in subjects with or without high altitude pulmonary edema-history.

Authors:  Isabelle Pham; Grégoire Wuerzner; Jean-Paul Richalet; Séverine Peyrard; Michel Azizi
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017

Review 7.  Endothelin receptors and their antagonists.

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Semin Nephrol       Date:  2015-03       Impact factor: 5.299

8.  The role of endothelin B receptor in bone modelling during orthodontic tooth movement: a study on ETB knockout rats.

Authors:  S Ibrahimi Disha; B Furlani; G Drevensek; A Plut; M Yanagisawa; S Hudoklin; I Prodan Žitnik; J Marc; M Drevensek
Journal:  Sci Rep       Date:  2020-08-26       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.